Evidence map›Paper›PMID 9736651›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience1998

Perforin-dependent neurologic injury in a viral model of multiple sclerosis.

P D Murray, D B McGavern, X Lin, M K Njenga, J Leibowitz, L R Pease, M Rodriguez

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Dimethyl fumarate may still have a role in progressive multiple sclerosis.Therapeutic advances in neurological disorders · 2016
    Article
  6. Article
  7. Article
  8. CD8(+) T cells in multiple sclerosis.Expert opinion on therapeutic targets · 2013
    Review
  9. Article
  10. Article
  11. Immunity and inflammation in neurodegenerative diseases.American journal of neurodegenerative disease · 2013
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Inflammation on the mind: visualizing immunity in the central nervous system.Current topics in microbiology and immunology · 2009
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

P D MurrayDepartment of Immunology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
D B McGavern
X Lin
M K Njenga
J Leibowitz
L R Pease
M Rodriguez
Mayo Clinic · USTexas College · US

Funding

T cell Function in Murine Model of Multiple SclerosisR01NS032129 · NINDS · MAYO CLINIC ROCHESTER · PI RODRIGUEZ, MOSES · 1994 to 2010
$2.7M
IMMUNE PROMOTION OF REMYELINATIONR01NS024180 · NINDS · MAYO CLINIC ROCHESTER · PI RODRIGUEZ, MOSES · 1987 to 2008
$2.7M
NINDS NIH HHS R01 NS024180NINDS NIH HHS R01 NS032129NINDS NIH HHS R01 NS24180NINDS NIH HHS R01 NS32129
6 · The paper itself

Abstract

In this study we demonstrate perforin-mediated cytotoxic effector function is necessary for viral clearance and may directly contribute to the development of neurologic deficits after demyelination in the Theiler's murine encephalomyelitis virus (TMEV) model of multiple sclerosis. We previously demonstrated major histocompatability complex (MHC) class I-deficient (beta2m-deficient) mice with an otherwise resistant genotype develop severe demyelination with minimal neurologic disease when chronically infected with TMEV. These studies implicate CD8(+) T cells as the pathogenic cell in the induction of neurologic disease after demyelination. To determine which effector mechanisms of CD8(+) T cells, granule exocytosis or Fas ligand expression, play a role in the development of demyelination and clinical disease, we infected perforin-deficient, lpr (Fas mutation), and gld (Fas ligand mutation) mice with TMEV. Perforin-deficient mice showed viral persistence in the CNS, chronic brain pathology, and demyelination in the spinal cord white matter. Perforin-deficient mice demonstrated severely impaired MHC class I-restricted cytotoxicity against viral epitopes, but normal MHC class II-restricted delayed-type hypersensitivity responses to virus antigen. Despite demyelination, virus-infected perforin-deficient mice showed only minimal neurologic deficits as indicated by clinical disease score, activity monitoring, and footprint analysis. Perforin- and MHC class II-deficient mice (with functional CD8(+) T cells and perforin molecules and an H-2(b) haplotype) had comparable demyelination and genotype, however, only the latter showed severe clinical disease. Gld and lpr mice demonstrated normal TMEV-specific cytotoxicity and maintained resistance to TMEV-induced demyelinating disease. These studies implicate perforin release by CD8(+) T cells as a potential mechanism by which neurologic deficits are induced after demyelination.

Indexed as

TheilovirusAnimalsChronic DiseaseDemyelinating DiseasesDisease Models, AnimalExocytosisFas Ligand Proteinfas ReceptorFemaleHistocompatibility Antigens Class IMaleMembrane GlycoproteinsMiceMice, Inbred C57BLMice, Mutant StrainsMicroscopy, ElectronFas Ligand ProteinFasl protein, mousefas ReceptorHistocompatibility Antigens Class IMembrane GlycoproteinsPerforinPore Forming Cytotoxic Proteins

Identifiers

PMID9736651
PMCPMC6793251
OpenAlexW1665248256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.